Optimi Health is trading 7.2% lower at $2.32, with the decline appearing more consistent with biotechnology-sector pressure than a company-specific catalyst. - No clear company-specific announcement or event explaining the November 2, 2026 decline was identified; the latest reported company milestones predate this session. - Biotechnology stocks were down 2.39% during the regular session. - Broader U.S. indices were higher, also pointing toward sector pressure.